Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer

This study has been completed.

Study NCT00006486 Information provided by National Cancer Institute (NCI)

First Received: November 6, 2000 Last Updated: July 23, 2008 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J, Ratain MJ. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 1;23(16):3726-32. Erratum in: J Clin Oncol. 2005 Jul 20;23(21):4808. Ratain, Mark J [added].

Stadler WM, Rosner G, Rini B, et al.: Successful implementation of the randomized discontinuation trial design (RDTD) with the putative antiangiogenic agent carboxyaminoimidazole (CAI) in renal cell carcinoma (RCC). A Cancer and Leukemia Group B (CALGB) Study. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-773, 2003.